| Title: | Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm |
| Journal: | Nutrition Metabolism and Cardiovascular Diseases |
| Published: | 20 Nov 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38161123/ |
| DOI: | https://doi.org/10.1016/j.numecd.2023.11.004 |
Publication 9261
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND AIMS: Abdominal aortic aneurysm (AAA) is the second most common aortic pathological manifestation. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a wide impact on the cardiovascular system and may be a risk factor for AAA. The aim of this study was to investigate whether MAFLD is associated with the risk of AAA.</p>
METHODS AND RESULTS: We used data from the prospective UK Biobank cohort study. MAFLD is defined as hepatic steatosis plus metabolic abnormality, type 2 diabetes, or overweight/obesity. AAA is collected by ICD-10 code. Cox regression was established to analyze the association between MAFLD and AAA. A total of 370203 participants were included; the average age of the participants was 56.7 ± 8.0 years, and 134649 (36.4 %) were diagnosed with MAFLD. During the 12.5 years of follow-up, 1561 (0.4 %) participants developed AAA. After fully adjusting for confounding factors, individuals with MAFLD had a significantly increased risk of AAA (HR 1.521, 95 % CI 1.351-1.712, p < 0.001). Importantly, the risk of AAA increases with the severity of MAFLD as assessed by fibrosis scores. These associations were consistent according to sex, weight, and alcohol consumption but weaker in elderly or diabetics (P for interaction <0.05). The association between the MAFLD phenotype and AAA was independent of the polygenic risk score. Additionally, MAFLD was not associated with thoracic aortic aneurysm or aortic dissection events.</p>
CONCLUSIONS: There was a significant relationship between MAFLD and AAA. These findings strongly recommend early prevention of AAA by intervening in MAFLD.</p>
10 Authors
- Yu Jia
- Yizhou Li
- Jing Yu
- Wenli Jiang
- Yi Liu
- Rui Zeng
- Zhi Wan
- Xiaoyang Liao
- Dongze Li
- Qian Zhao
1 Application
| Application ID | Title |
|---|---|
| 112111 | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease |
Enabling scientific discoveries that improve human health